Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
November 2015
-
Media ReleaseRegulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDASandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking…
-
Media ReleaseFLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbationsUltibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to confirm Ultibro…
-
Media ReleaseAlcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual MeetingNearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better[1] in clinical study Alcon is the first refractive laser manufacturer to receive FDA…
-
Media ReleaseNovartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patientsNew x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on…
-
Media ReleaseNew two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitisA sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained…
-
Media ReleaseNovartis nominating Elizabeth Doherty and Ton Buechner to the Board of DirectorsNominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms.…
October 2015
-
Media ReleaseNovartis Foundation and partners launch new hypertension program in GhanaCommunity-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control Screening and treatment is shifted to the…
-
Media ReleaseNovartis delivered strong core margin expansion (cc) and continued to strengthen the pipeline in Q3; on track for full-year guidanceSolid growth (cc[1]) in Q3 sales, core operating income, core EPS for continuing operations[2] Net sales were USD 12.3 billion (-6%, +6% cc) Operating income was USD 2.2 billion (-18%, +2% cc) Core…
-
Media ReleaseNovartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritisCosentyx (secukinumab) is recommended for approval in Europe for the treatment of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients Cosentyx demonstrated rapid onset of…
-
Media ReleaseNovartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and PalobiofarmaWith four programs currently in clinical trials and five more expected to enter the clinic by the end of 2016, Novartis has rapidly built a robust portfolio of programs focused on stimulating the…
-
Media ReleaseKenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseasesNovartis Access is a first-of-its-kind portfolio of products aimed at increasing access to medicines against cardiovascular diseases, diabetes, respiratory illnesses and breast cancer in low- and…
-
Media ReleaseNovartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 yearsLate-breaking data at EADV show that 8 out of 10 of psoriasis patients (83%) achieved 75% skin clearance (PASI 75) with CosentyxTM after three years[1] 6 out of 10 patients (64%) had…
Pagination
- ‹ Previous page
- 1
- …
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- …
- 88
- › Next page